coenzyme Q10/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
Decreases tumour necrosis factor alpha concentration
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×2“The subjects in the Q10-300 group had a significantly lower level of TNF-α than those in the placebo group at week 12 (P = 0.039).”
Quoted verbatim from Effects of coenzyme Q10 supplementation (300 mg/day) on antioxidation and anti-inflammation in coronary artery disease patients during statins therapy: a randomized, placebo-controlled trial.. - Study
- RCT
- Duration
- 3 months
- Dose
- 300 mg/day (150 mg twice daily) for 12 weeks
- Population
- Patients with coronary artery disease on statin therapy for at least one month; single-blind placebo-controlled trial, 42 completers (placebo n = 19, coenzyme Q10 n = 23); week 12 between-group comparison
Effects of coenzyme Q10 supplementation (300 mg/day) on antioxidation and anti-inflammation in coronary artery disease patients during statins therapy: a randomized, placebo-controlled trial.2013PMID:24192015Permalink
Keep reading
- Everything the graph holds on coenzyme Q10
- Every compound studied against Tumour necrosis factor alpha concentration
- How to read the evidence strength and the marks
To cite this finding: https://catalystproject.ai/e/01M45QQ1DEREQFS93NGPANM937